Salud financiera de hoja de balance de Ajanta Pharma
Salud financiera controles de criterios 6/6
Ajanta Pharma tiene un patrimonio de accionistas total de ₹34.8B y una deuda total de ₹330.2M, lo que sitúa su ratio deuda-patrimonio en 0.9%. Sus activos y pasivos totales son ₹44.3B y ₹9.5B respectivamente. El BAIT de Ajanta Pharma es de ₹9.2B, por lo que su ratio de cobertura de intereses es de -558.2. Tiene efectivo e inversiones a corto plazo que ascienden a ₹4.8B.
Información clave
0%
Ratio deuda-patrimonio
₹0
Deuda
| Ratio de cobertura de intereses | 143.8x |
| Efectivo | ₹4.61b |
| Patrimonio | ₹35.67b |
| Total pasivo | ₹10.71b |
| Activos totales | ₹46.38b |
Actualizaciones recientes sobre salud financiera
We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease
Feb 23
Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Aug 26These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well
Feb 07Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Mar 14Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?
Aug 26Recent updates
Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results
May 05Ajanta Pharma Limited's (NSE:AJANTPHARM) Intrinsic Value Is Potentially 23% Below Its Share Price
Apr 05We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease
Feb 23Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected
Dec 23Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Aug 26These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well
Feb 07Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors
Oct 24Estimating The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Aug 25Is Now The Time To Put Ajanta Pharma (NSE:AJANTPHARM) On Your Watchlist?
Jul 19A Look At The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Apr 28Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Mar 14I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut
Feb 06Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Dec 13Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50
Oct 31Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Is Well Worth Watching
Sep 22Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 27% Discount?
Sep 08Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?
Aug 26Here's Why Shareholders Will Not Be Complaining About Ajanta Pharma Limited's (NSE:AJANTPHARM) CEO Pay Packet
Jul 07Should You Be Adding Ajanta Pharma (NSE:AJANTPHARM) To Your Watchlist Today?
Jun 14Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 30% Discount?
May 15Ajanta Pharma Limited (NSE:AJANTPHARM) Vies For A Place In Your Dividend Portfolio: Here's Why
Apr 10Ajanta Pharma Limited's (NSE:AJANTPHARM) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?
Mar 11Does Ajanta Pharma (NSE:AJANTPHARM) Deserve A Spot On Your Watchlist?
Feb 24The Ajanta Pharma (NSE:AJANTPHARM) Share Price Is Up 56% And Shareholders Are Holding On
Jan 30
What Can We Make Of Ajanta Pharma's (NSE:AJANTPHARM) CEO Compensation?
Jan 18Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Jan 06What Percentage Of Ajanta Pharma Limited (NSE:AJANTPHARM) Shares Do Insiders Own?
Dec 25You Have To Love Ajanta Pharma Limited's (NSE:AJANTPHARM) Dividend
Dec 13Is Ajanta Pharma Limited's (NSE:AJANTPHARM) Recent Stock Performance Influenced By Its Financials In Any Way?
Dec 01With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Is Interesting
Nov 19Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (₹25.6B) de AJANTPHARM superan a sus pasivos a corto plazo (₹8.0B).
Pasivo a largo plazo: Los activos a corto plazo de AJANTPHARM (₹25.6B) superan a sus pasivos a largo plazo (₹1.5B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: AJANTPHARM está libre de deudas.
Reducción de la deuda: AJANTPHARM no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 2.3%.
Cobertura de la deuda: AJANTPHARM no tiene deuda, por lo tanto no necesita estar cubierta por flujo de caja operativo.
Cobertura de intereses: AJANTPHARM no tiene deuda, por lo que la cobertura de pagos de intereses no es motivo de preocupación.